Human mu‐opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin‐induced painful neuropathy

• DOI: 10.1002/cncr.26430
• Publication Date: 2011-08-11T17:30:12Z
• Authors: Yu‐Chang Liu; Wei‐Shu Wang
• Keywords: Acetaminophen

The A118G polymorphism of the mu-opioid receptor gene (OPRM1), resulting in substitution an amino acid, has been found to be associated with functional effects and response opioid treatment. purpose this study was assess whether contributes variability tramadol/acetaminophen combination tablets (Ultracet) for treating oxaliplatin-induced painful neuropathy.A total 96 patients adenocarcinoma colon or rectum (n = 84), stomach 12) who had developed neuropathy were enrolled. Ultracet administered at 1 tablet every 6 hours, pain assessed scored using a visual analog scale (VAS). OPRM1 examined polymerase chain reaction-direct sequencing method.The allelic frequency variant (118G) allele 39.6%, prevalence OPRM1-118 AA, AG, GG genotypes 31.3% 30), 58.3% 56), 10.4% 10), respectively. For all patients, mean pre-treatment post-treatment VAS scores 3.1 2.1, respectively (P < .001). Patients AA genotype better analgesic effect than those G variants (AG genotypes). Pre-treatment 2.6, respectively; however, genotype, 3.0 0.9, requirement rescue analgesia also higher .01).These data suggest that is effective management neuropathy. OPRM1, by altered function consequential on agents, could key determinant decreased Ultracet.